On October 29, 2026, GoodRx announced the market-wide launch of Employer Direct, a weight loss offering that lets employers help employees access FDA-approved GLP-1 medications for weight management outside the traditional pharmacy benefit. The announcement came one day after WTW reported that employer GLP-1 coverage for weight loss fell to 53%, down from 57%.
Employer Direct is built for the gap that survey describes: employers that want to support GLP-1 access but do not cover these drugs under their health plan, or want a more predictable way to pay for them.
The five medications
Employer Direct provides access to employer pricing made available by the manufacturers for five medications:
- Wegovy (semaglutide) — the weekly injection pen.
- Wegovy HD (semaglutide) — Novo Nordisk's higher-dose weekly pen, 7.2 mg.
- Wegovy pill (oral semaglutide) — the once-daily tablet form of semaglutide.
- Foundayo (orforglipron) — Eli Lilly's once-daily oral GLP-1.
- Zepbound KwikPen (tirzepatide) — Eli Lilly's tirzepatide in the KwikPen device.
GoodRx collaborates with Novo Nordisk on employer pricing, and serves as an approved independent program administrator for Lilly Employer Connect, Eli Lilly's employer platform. The announcement does not break down which manufacturer channel covers each of the five medications. Wegovy employer pricing is available at retail pharmacies nationwide, according to Novo Nordisk.
How employers choose medications and contributions
Employer Direct puts three decisions in the employer's hands:
Choose the medications. Employers determine which of the five eligible FDA-approved GLP-1 medications for weight management to include. An employer can offer all five or a subset, based on workforce needs and benefits strategy.
Set the contribution. Employers choose how much to contribute toward the manufacturer pricing, as a fixed amount, a percentage, or full coverage. Contributions are applied automatically when prescriptions are filled, with no reimbursement step for the employee.
Add clinical care. Employers can integrate GoodRx for Weight Loss into the offering, connecting clinical care, transparent pricing, and pharmacy fulfillment. Employees can also participate with a valid prescription from their own healthcare provider.
The offering is designed to complement an employer's existing health plan, not replace it. It provides targeted support for medications that may not otherwise be covered within the traditional benefit.
Implementation in as little as 30 days
GoodRx says employers can configure the offering based on their workforce and benefits strategy, with implementation as quick as 30 days. The offering is available to employers, plan sponsors, consultants, and third-party administrators. Employers interested in the program can learn more at goodrx.com/employerdirect.
Employer Direct builds on GoodRx's existing manufacturer relationships through its Pharma Direct business.
Get GLP-1 price and coverage changes by email
Self-pay prices, savings cards and insurer coverage changes, checked and explained. One free email a week.
GoodRx Companion coming January 2027
Beginning January 2027, employers will also be able to offer GoodRx Companion through Employer Direct. Companion is a fixed monthly subscription that provides free and low-cost generic medications and savings on common healthcare services, including dental, vision, labs, and imaging. Employers can offer Companion on its own or alongside the weight loss offering.
What this means if you are an employee
If your employer does not cover GLP-1s under its health plan, ask your HR or benefits team whether the company offers GoodRx Employer Direct or plans to. Three questions to ask:
- Which of the five medications are included?
- How much does the employer contribute — a fixed amount, a percentage, or full coverage?
- Do you use GoodRx for Weight Loss for clinical care, or do you bring a prescription from your own provider?
Your out-of-pocket cost depends on the answers. GoodRx did not publish per-drug employer prices in the announcement, so the amount you pay is set by your employer's contribution choice, not by a public price list.
If your employer does not offer Employer Direct, manufacturer self-pay programs are the other route to the same brand-name drugs. Our GLP-1 insurance coverage guide covers prior authorization, appeals, and savings programs.
What we could not confirm
- Exact employee prices. The announcement does not publish dollar prices for the Novo employer pricing or a per-drug employee cost. Pharmaceutical Commerce reported that Lilly Employer Connect makes Zepbound KwikPen available at $449 across all doses, but that figure comes from trade coverage, not from the GoodRx announcement, and we could not confirm it against a primary source.
- Eligibility rules. The announcement does not state which employees qualify (for example, BMI thresholds or prior authorization rules). Those terms are set by the employer and the plan, so check with your benefits team.
This article is educational information, not medical advice. Talk to your prescriber before starting, changing, or stopping any medication. Pricing and program details were checked in November 2026 and can change.
Sources
- GoodRx, "GoodRx Launches Employer Direct Weight Loss Offering" (press release, October 29, 2026). Business Wire
- Pharmaceutical Commerce, "Pharma Pulse: GoodRx Opens Employer GLP-1 Channel, Lilly Fends Off Novo Ad Challenge, PCMA Takes Aim at Wholesalers" (October 2026). Pharmaceutical Commerce
- WTW, "WTW 2026 Best Practices in Healthcare Survey" (press release, October 28, 2026). GlobeNewswire





